chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Left arm soreness 1/2 hours after receiving injection along with nausea and vomiting. Started he felt nauseated for the rest of the day and went to bed early. Felt better the next morning.
Somewhat itchy. Two inch wide red stripe extending approx. 6 inches up her arm per patient phone call. Advised her to notify her physician.
I began to have Chronic Spontaneous Urticaria after COVID-19 vaccine. I wake up with hives on my face, neck, arms and legs if I do not take antihistamines on a strict schedule. It?s MISERABLE. I wish I never had to Covid vaccine. I am unable to exercise due to the hives triggering with workouts.  I have seen my pcp and prescribed prednisone but it has not helped. There are a whole group of people this has also happened too. I have taken prednisone, Zyrtec, xyzal, Ranitidine, omeprazole, amoxicillin and I have tried other antihistamines. No real relief. Continuing to have huge out breaks.
Patient was seen at Hospital ER around 11:15 am. on 4/23/18. Patients C/O- mild SOB, throat swelling, lightheadedness, and nausea 1 hr. after injection No apparent distress, otherwise, otherwise healthy patient. Medication given at ER BENADRYL oral 25mg, PEPCID oral 40mg, and Prednisone oral 60mg. Prescriptions - Prednisone 10 mg, BENADRYL 25 mg, PEPCID 20 mg, EPIPEN x 2. Pt. was discharged home and condition stable. Follow up in 1-2 weeks. Pt. states she received Tdap week before and had a reaction to that injection also. Pt. did not received the Tdap at the health department.
Numbness and tingling in right arm. It started the night of 1/21/21 and is still happening. Intermittently it feels like my arm and fingers are falling asleep.
baby developed hives at site of injection x 20 minutes.  Given Benadryl PO x1 with resolution of hives.  No other sx
A report was received from a health care professional on 12/2/03 concerning a vaccine, demography unknown who inadvertently received Fluvirin via the SC route on 12/2/03. On 12/2/03, the vaccinee inadvertently received Fluvirin via the SC route. No adverse symptoms were reported at the time of reporting. There was insufficient information to determine the reporter's causality assessment. Follow up pending.
Had shingles shot on 06/13/08. Became very ill 24 hours later. My arm swelled for 4-5 days with welts and I had diarrhea, vomiting and felt feverish. Paid $195.00 to get sick!
Initial report received on 09 October 2013 from a health care professional. A 60-year-old male patient whose medical history and concomitant medications were not reported, received a dose of FLUZONE ID (lot number UH904AA, expiration date 30-Jun-2014) by unknown route and site of vaccination was deltoid 19-Sep-2013. It was reported that a patient over 60-year-old have received a FLUZONE ID. On 19-Sep-2013, patient reported soreness at the injection site. It has been 3 weeks and there is more pain. Trouble lifting his arm up. Hurting in the area where it was injected. List of documents held by sender: none.
Examined prior to vax - normal; Given vax w/in 5min had swelling of face, wheezing; Given Epinephrine x 3 next 20 min; Became cyanotic p/first epi, as wheezing cont;
had a severe allergic reaction; he couldn't move for two weeks; schedule to take the Moderna shoot as a second dose; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): MOD22-001325 .  A 56 year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. Relevant medical history included: "immunocompromise for kidney transplant" (unspecified if ongoing); "lupus" (unspecified if ongoing); "Wagner's disease" (unspecified if ongoing). Concomitant medication(s) included: ZORTRESS; AZATHIOPRINE. The following information was reported: HYPERSENSITIVITY (non-serious), outcome "unknown", described as "had a severe allergic reaction"; MOVEMENT DISORDER (non-serious), outcome "unknown", described as "he couldn't move for two weeks"; CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR (non-serious), outcome "unknown", described as "schedule to take the Moderna shoot as a second dose".  Additional information: patient call because they took the Pfizer vaccine and had a severe allergic reaction. They mentioned that they were immunocompromise for kidney transplant, and that they had lupus and Wagner's disease. Also that they were schedule to take the Moderna shoot as a second dose, and its worry was going to have the same reaction. Also he mentioned that he couldn't move for two weeks and had no antibody's and couldn't leave the house.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
RN administered PCV13 to client who should have received PPSV23. RN consulted with medical supervisor today and attempted to notify the client regarding error. RN will attempt again to reach client regarding error.
Around 2am, I woke up and went to the bathroom.  I fainted and hit my head on the floor.   I have never fainted before.  After my husband woke me up, I threw up multiple times.
Little bit of itching; Bruise on the center; Lump on her skin; skin Warm; Rash grew to 3 to 4 inches and going around the arm (spreading); Little rash; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PRURITUS (Little bit of itching), CONTUSION (Bruise on the center), MASS (Lump on her skin), SKIN WARM (skin Warm) and RASH (Little rash) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history reported.  Concomitant products included TRAMADOL for an unknown indication.   On 23-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Jan-2021, the patient experienced RASH (Little rash). On 30-Jan-2021, the patient experienced PRURITUS (Little bit of itching), CONTUSION (Bruise on the center), MASS (Lump on her skin), SKIN WARM (skin Warm) and RASH (Rash grew to 3 to 4 inches and going around the arm (spreading)). On 26-Jan-2021, RASH (Little rash) had resolved. At the time of the report, PRURITUS (Little bit of itching), CONTUSION (Bruise on the center), MASS (Lump on her skin), SKIN WARM (skin Warm) and RASH (Rash grew to 3 to 4 inches and going around the arm (spreading)) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information provided included acetaminophen.
5 days ago her daughter had a runny nose and cough; 5 days ago her daughter had a runny nose and cough; This is a spontaneous report from a contactable consumer (mother) received from Pfizer-sponsored program. A 17-years-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE: Solution for injection), dose 1 via an unspecified route of administration on 06Apr2021 (Batch/Lot number was not reported) as single dose for covid-19 immunisation. The patient medical history and concomitant medications were not reported. on Apr2021, the patient experienced 5 days ago her daughter had a runny nose and cough. Her daughter got the 1st dose 06Apr2021 and the 2nd dose schedule supposed to be on 27Apr2021, but they rescheduled the 2nd dose on 01May2021 because 5 days ago her daughter had a runny nose and cough. The action taken in response to the events for bnt162b2 was not applicable. The outcome of event was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
sore and achy all over; headache; sore arm at injection site; soreness and achiness progressed; This is a spontaneous report from a contactable consumer. A 45-years-old male patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: EL3247) via an unspecified route of administration, administered in Arm Right on 11Feb2021 09:45 at single dose for covid-19 immunization. The patient medical history was not reported. Historical vaccine included the patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: EL3247) via an unspecified route of administration, administered in Arm Right on 21Jan2021 09:45 at single dose for covid-19 immunization. Concomitant medications included loratadine (ALAVERT) taken for an unspecified indication and melaleuca multivitamins/minerals. As per adverse event description, on 11Feb2021 18:00, sore and achy all over, headache, sore arm at injection site, but not right away, it took until the evening the same day as the 2nd injection. The soreness and achiness progressed a bit more from the evening into the morning, today. I felt nothing at all after the first injection. The patient did not received treatment. Upon follow up, it was confirmed that he mentioned that he noticed the onset on 11Feb2021 at around 6 pm, the start of it, but then felt the symptoms increase into the night and then more so the next morning on 12Feb2021. The outcome of events not recovered.  No follow-up attempts are possible. No further information was provided.
Severe chills for several hours during the night; 3 degree temperature in the morning; soreness that spread from waist to feet over the course of several hours; discomfort at site of vaccine; weakness in arm where vaccine was administered; felt terrible for about 24 hours.
Interchange of vaccine products; Was vaccinated for COVID-19 and then tested positive; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Was vaccinated for COVID-19 and then tested positive) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect products included non-company products TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for an unknown indication and REMDESIVIR for an unknown indication.    No Medical History information was reported.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form, first dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form On an unknown date, received second dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) dosage was changed to 1 dosage form. and REMDESIVIR (unknown route) at an unspecified dose. On 19-May-2022, the patient experienced COVID-19 (Was vaccinated for COVID-19 and then tested positive). On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products). At the time of the report, COVID-19 (Was vaccinated for COVID-19 and then tested positive) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 19-May-2022, SARS-CoV-2 test: positive (Positive) Positive.         Concomitant medication was not provided. Patient was prescribed with Paxlovid as antiviral treatment but caller said that he has not taken the drug Paxlovid yet.  Company comment.  This spontaneous case concerns a 66yearold male patient with no medical history reported, who experienced the unexpected, non  serious AESI of COVID  19, after a booster dose of mRNA-1273 vaccine; third dose of his COVID  19 immunization schedules; the patient previously had two doses of Pfizer COVID  19 vaccines (interchange of vaccine products.). Temporal association cannot be assessed due to lack of information on vaccination date. The report stated that the patient tested positive for COVID  19 and he wanted to get some antivirals. No further details were provided for medical review. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report; Sender's Comments: This spontaneous case concerns a 66  year  old male patient with no medical history reported, who experienced the unexpected, non  serious AESI of COVID  19, after a booster dose of mRNA-1273 vaccine; third dose of his COVID  19 immunization schedules; the patient previously had two doses of Pfizer COVID  19 vaccines (interchange of vaccine products.). Temporal association cannot be assessed due to lack of information on vaccination date. The report stated that the patient tested positive for COVID  19 and he wanted to get some antivirals. No further details were provided for medical review. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
9-19-05 RECEIVED HEP B#3, CAME INTO CLINIC ON 10-2-05 WITH C/O PAIN IN HER RIGHT SHOULDER. RETURNED TO CLINIC ON 10-6-05 WITH C/O PAIN & TENDERNESS IN HER RIGHT SHOULDER. SHE THOUGHT IT WAS FROM THE THIMEROSOL PERSERVATIVE IN THE VACCINES. SHE THEN RETURNED TO THE CLINIC ON 10-28-05 FOR HER HEP B TITER AND ASKED IF SHE COULD SEE THE PHYSICIAN'S ASSISTANT REGARDING HER SHOULDER TIGHTNESS AND SORENESS. SHE WAS PRESENTED IN THE CLINIC AS A F/U PATIENT FOR C/O SHOULDER TIGHTNESS & SORENESS FROM PREVIOUS C/O PAIN R/T HEP B INJECTION. DENIES MUCH REAL PAIN, JUST SORENESS & TIGHTNESS.
Information has been received from a health professional concerning a 2 month old black female with no medical history who on 16Oct03 was vaccinated IM in the left leg with the first dose of hep B virus vaccine rHBsAg (yeast) (+) Hib conj vaccine (OMPC) (Lot 646074/0369N). Concomitant vaccinations on that same day included an IM dose (1st) in the left leg of diphtheria toxoid (+) pertussis vaccine (unspecified) (+) tetanus toxoid (lot U0997DA), an IM dose (1st) in the right leg of polio virus vaccine inactivated (unspecified) (lot W10022) and an IM dose (1st) in the right leg of pneumococcal 4 6B 9V 14 18C 19F 23F conj vaccine (CRM 1997) (Prevnar) (lot 493266). There was no illness at the time of vaccination. The health professional reported that the pt subsequently developed a fever of 100.8 and swelling at the injection site. At the time of this report, medical attention had not been sought and the outcome was unk. Additional information has been requested.
7-8 cm circle area of raised red area that was hot and itchy lower than actual puncture site
This spontaneous report as received from a other health professional refers to a patient of unknown age and gender. Approximately one year ago in July 2012, the patient was vaccinated with the first dose of VARIVAX (dose, route and lot not reported) and required a second dose. No adverse effect reported. The outcome of the event was unknown. Additional information has been requested.
Patient with symptoms c/w partial seizure vs. hypotonia, hyporesponsiveness.  Almost immediately after recieving her 6 mo immunizations, episode where patient with head hyperextended, arms extended to side, left lateral fixed gaze with twitch of orbital muscles, as well as hyporesponsiveness lasting approximately 3-5 minutes followed by a more somnolent state for another 5-10 minutes  10/8/09 ICD-9 Codes service dates 8/7/09 to 8/8/09: 780.32 Atypical febrile sezure poss due to vaccination, 999.0 Generalized vaccinia as complication of medical care, 112.0 Candidiasis of the mouth, E948.4 Pertussis vaccine/pertussis component causing adverse effects in therapeutic use, E849.7 Injury of poisoning occurring at/in residential institution.
Information has been received from a registered nurse, and refers to an unspecified number of patients of unknown age and gender. No information was provided regarding the patients' medical history, concurrent conditions or concomitant medications. On unknown dates, the patients started therapy with ROTATEQ, (lot # and expiry date were not reported) for prophylaxis. The nurse reported, some unspecified patients had received dose 2 or 3 of the series later than recommended (timing unspecified) due to unspecified family situations not related to the vaccine. No adverse effects were noted in these patients. Follow up information was received from the health care professional who administered the vaccines on 11-JUN-2018. Upon follow up, it was determined that the patient is an 8 month female patient; therefore this case is now valid. It was also reported that an expired dose of ROTATEQ was administered orally to the patient on 24-APR-2018; lo# M025568 expiration date 07-NOV-2017. This was the patient's 3rd dose of ROTATEQ. The patient was also administered the 3rd dose of PREVNAR 13, intramuscularly in the right vastus lateralis Lot# R49358; PENTACEL intramuscularly in the left vastus lateralis, lot # C5368AA, and the third dose of hepatitis b virus vaccine (Glaxo Smith Kline) in the rigth vastus lateralis lot# FB2X4. No other adverse events were reported. This is one of 2 cases from the same reporter. Sender's Comments: US-009507513-1805USA002592.
mild fever, consistant and very large amount of mucus from nose and eyes, mild cough, crying, loss of appetite. He was getting choked on all of the mucus. It was mostly clear to White and a little yellow.
I have had a spotting/heavy period non stop since i received the first vaccine. Its ongoing to this date.
Employee stated after receiving the second dose of the Pfizer COVID-19 vaccine, she felt weak, was achy all over, and had a low grade fever of 100.8. Employee stated that she alternated taking Tylenol and Motrin for the aches and fever. The symptoms subsided after 2 days. The symptoms did not interfere with ADL's.
Reaction started  around 4 hrs after injection. Symptoms include dryness, edema, erythema of left deltoid arm. States seemed to be improving by the next day.
Initial solicited report received on 22 July 2015 and follow-up information received on 28 July 2015 from an investigator participating in a trial. This case involves a 12-year-old male subject who developed behavioral problems during the study participation. The subject had a medical history of autism spectrum disorder, mood disorder and attention deficit-hyperactivity disorder. The subject had no concomitant therapies. On 01 July 2015 i.e. 132 days after receiving a first intramuscular dose of meningococcal vaccine in the right deltoid on 19 February 2015, the subject developed behavioral problems (batch number- M14071). The event appeared after visit 2. The subject had associated symptoms of increased aggression started on 01 July 2015. The subject was hospitalized on 21 July 2015. On the request of the subject's mother for the mental health evaluation of the subject due to his behavior problems, the subject was brought to the emergency room. There were no specific findings for lab data. The corrective treatment was not reported. The symptom of increased aggression was ongoing at the time of this report. The event of behavioral problems was resolved on 25 July 2015. The subject was discharged from the hospital on 25 July 2015. According to the investigator, the event was not related to the study vaccine or trial procedures. Relationship to investigational product according to company: not associated. The serious adverse event did not lead to the termination of the subject from the study. List of documents held by sender: none. Follow up information received on 04 August 2015. The subject received corrective treatment with TOPAMAX to help with appetite control. Follow up information received on 28 August 2015. It was confirmed that there were no other treatment plans other than the addition of TOPAMAX to control appetite as that was what his behavior concerns were stemming from. No additional therapies were given or prescribed. Follow up information received on 04 September 2015. The subject received concomitant medication with PROZAC, INTUNIV, SINGULAIR, PATANASE, Melatonin, NASONEX, TRILEPTAL, RISPERDAL and ZYRTEC. The subject received corrective treatment with behavioral group therapy. According to the investigator, the event was not related to the concomitant medications given.
Reports having a hot, itchy, welt at vaccine administration site and flat itchy rash at waistline and upper torso which began 3 days post vaccination.  Recently self administered Benadryl with no relief at the time of call. Instructed to contact PCP to consult regarding symptoms and second dose.  Instructed to inform Nurse of reaction, treatment, and outcome when return for second appointment and being assessed.
Went to exercise after injection. Became weak experiencing "rubbery legs" to where had to stop exercising. Began feeling "bad all over" like flu-like symptoms. Legs weak. Injection site became swollen & hot to touch which lasted 5 days. Felt OK for 2 days but then on 4-8-19 awoke to find mouth burning & had very painful "sores" on right side of mouth on gums & roof of mouth which lasted 7 days. Awoke on 4-15-19 feeling much better with no complaints.
Fever 103.5, sore red injection site, fussiness, sleeplessness, not eating for over 6 hours, shrill screaming for over 3 hours.  All symptoms lasted for 3 days.  Also has a rough scaly dry spot on both legs where the injection was.  This has yet to disappear.
This spontaneous report as received from a physician refers to a patient who was a little over 9 months old. The patient was vaccinated with ROTATEQ for the first time on 06-FEB-2012. Second dose was administered on 30-APR-2012. No other co-suspects were reported. No concomitant medications were reported. The patient was given the third dose of ROTATEQ when the patient was a little over nine months old, on 26-SEP-2012. No adverse effects reported and there was no PQC involved. Additional information is not expected.
Patient got very pale and said "I don't feel good", immediately following vaccination with Meningococcal vaccine and Yellow Fever vaccine.  Her eyes then rolled back, and she got very stiff and made guttural throat noises, and postured with arms straight out, fisted hands.  She appeared to be having a seizure.  Her mom and I got her lowered from the chair to the floor, and observed her closely.  I assessed her, noting that she was breathing.  Seizure-like activity continued for about 20 seconds.  Then patient became conscious and was given oxygen administration by mask at 4L via oxygen tank, for a couple of minutes.  Then she sat up in chair, and drank some apple juice we gave her.  I called Clinic (where her PCP is) and spoke to Dr. He said that mom could take her to the urgent care in Clinic and see Dr., and they would get her added to his schedule.  We also advised mom that if patient had any further problems or similar behavior on the way there, to pull over and dial 911.  Mom agreed.  We observed the patient for several minutes before she left; she was alert, oriented, vital signs (breathing and pulse were normal, pink color), said she felt better.
2 1/2 inflamed, hot area 3cm below site of flu infect; started about 10AM, by 1PM c/o nausea, chills, weakness & aching;
Injection site swelling, burning, redness, pain post injection to current day still pain, swelling and burning